Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AKTX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

0.52

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-0.33

EPS This/Next Y

0.03

Price

0.13

Target Price

1

Analyst Recom

1

Performance Q

-52.73

Upside

-13,023.1%

Beta

0.54

Ticker: AKTX



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27AKTX0.2399N/AN/A0
2026-03-02AKTX0.2355N/AN/A0
2026-03-03AKTX0.2334N/AN/A0
2026-03-04AKTX0.2459N/AN/A0
2026-03-05AKTX0.2481N/AN/A0
2026-03-06AKTX0.2535N/AN/A0
2026-03-09AKTX0.2543N/AN/A0
2026-03-10AKTX0.257N/AN/A0
2026-03-11AKTX0.2631N/AN/A0
2026-03-12AKTX0.2625N/AN/A0
2026-03-13AKTX0.2567N/AN/A0
2026-03-17AKTX0.2199N/AN/A0
2026-03-18AKTX0.1603N/AN/A0
2026-03-19AKTX0.1432N/AN/A0
2026-03-20AKTX0.132N/AN/A0
2026-03-23AKTX0.1444N/AN/A0
2026-03-24AKTX0.136N/AN/A0
2026-03-25AKTX0.1354N/AN/A0
2026-03-26AKTX0.1364N/AN/A0
2026-03-27AKTX0.1307N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27AKTX0.24- 10.3-0.33
2026-03-02AKTX0.24- 10.3-0.33
2026-03-03AKTX0.24- 10.3-0.33
2026-03-04AKTX0.25- 9.9-0.33
2026-03-05AKTX0.25- 9.6-0.33
2026-03-06AKTX0.25- 9.6-0.33
2026-03-09AKTX0.25- 9.8-0.33
2026-03-10AKTX0.26- 9.5-0.33
2026-03-11AKTX0.26- 9.6-0.33
2026-03-12AKTX0.25- 9.9-0.33
2026-03-13AKTX0.23- 10.5-0.33
2026-03-17AKTX0.22- 10.6-0.33
2026-03-18AKTX0.16- 12.3-0.33
2026-03-19AKTX0.14- 12.8-0.33
2026-03-20AKTX0.13- 13.0-0.33
2026-03-23AKTX0.14- 13.1-0.33
2026-03-24AKTX0.14- 13.1-0.33
2026-03-25AKTX0.14- 12.8-0.33
2026-03-26AKTX0.14- 12.8-0.33
2026-03-27AKTX0.13- 12.9-0.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27AKTX19.1913.610.77
2026-03-02AKTX0.0013.160.77
2026-03-03AKTX0.0013.160.77
2026-03-04AKTX0.0013.160.77
2026-03-05AKTX0.0013.160.77
2026-03-06AKTX0.0013.160.77
2026-03-09AKTX0.0013.160.77
2026-03-10AKTX0.0013.160.77
2026-03-11AKTX0.0013.160.64
2026-03-12AKTX0.0013.160.64
2026-03-13AKTX0.0013.160.64
2026-03-17AKTX0.0013.160.64
2026-03-18AKTX0.0013.160.64
2026-03-19AKTX0.0013.160.64
2026-03-20AKTX0.0013.160.64
2026-03-23AKTX0.0013.160.64
2026-03-24AKTX0.0013.160.64
2026-03-25AKTX0.0013.160.52
2026-03-26AKTX0.0013.160.52
2026-03-27AKTX0.0013.160.52
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

Institutional Transactions

13.16

Beta

0.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

19

Sentiment Score

16

Actual DrawDown %

99.8

Max Drawdown 5-Year %

-99.8

Target Price

1

P/E

Forward P/E

PEG

P/S

P/B

0.18

P/Free Cash Flow

EPS

-0.48

Average EPS Est. Cur. Y​

-0.33

EPS Next Y. (Est.)

-0.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.01

Return on Equity vs Sector %

-96.9

Return on Equity vs Industry %

-80.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.12

EBIT Estimation

12.9
◆ AKTX Healthcare
$0.13
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
13/25
Volume
4/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
25
Range 1M
3.3%
Sup Dist
0.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
26 /100
WEAK
Momentum
0/25
Growth
20/30
Estimates
0/20
Inst/Vol
6/15
Options
0/10
EPS Yr
87.6%
EPS NY
20%
52W%
0.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +669.2% upside
Quality
2/30
Valuation
16/30
Growth
16/25
Stability
5/10
LT Trend
1/5
Upside
+669.2%
Quality
12
Click a card to see score breakdown Full Analysis →
Akari Therapeutics Plc
Sector: Healthcare
Industry: Biotechnology
Employees: 8
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
AKTX

Latest News

—
Caricamento notizie per AKTX…
stock quote shares AKTX – Akeso Inc. Stock Price stock today
news today AKTX – Akeso Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKTX – Akeso Inc. yahoo finance google finance
stock history AKTX – Akeso Inc. invest stock market
stock prices AKTX premarket after hours
ticker AKTX fair value insiders trading